Roche’s immunotherapy Tecentriq combined with the Swiss drugmaker’s Avastin medicine helped people with the most common form of liver cancer to live longer than with an older drug from Germany’s Bayer.

Eisai and Merck announced that the U.S. FDA approved the kinase inhibitor Lenvima (lenvatinib) for the first-line treatment of patients with unresectable hepatocellular carcinoma.